Literature DB >> 2966965

Duration of effect of oral diphosphonate therapy in Paget's disease of bone.

R E Gray1, A J Yates, C J Preston, R Smith, R G Russell, J A Kanis.   

Abstract

The effects of the diphosphonates etidronate and clodronate were studied in 144 patients with Paget's disease. All five programmes of treatment tested induced a similar suppression of disease activity as judged by serum alkaline phosphatase concentrations, but the proportion of patients responding and the duration of responses differed significantly between programmes. The proportion responding to etidronate 5-10 mg/kg/day for six months was less than for other regimens, and the most sustained response was after treatment with clodronate 1600 mg daily for six months. More complete biochemical suppression was associated with the more prolonged responses irrespective of the regimen used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2966965

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  16 in total

Review 1.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Degeneration of Paget's disease into sarcoma: clinical and therapeutic influencing factors.

Authors:  Alessandro Zati; Teresa Wanda Bilotta
Journal:  Chir Organi Mov       Date:  2008-04-12

4.  Long-term control of Paget's disease of bone with low-dose, once-weekly, oral bisphosphonate preparations, in a "real world" setting.

Authors:  Yair Liel; Muhammad Abu Tailakh
Journal:  Endocrine       Date:  2018-11-08       Impact factor: 3.633

5.  A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone.

Authors:  W D Fraser; T C Stamp; R A Creek; J P Sawyer; C Picot
Journal:  Postgrad Med J       Date:  1997-08       Impact factor: 2.401

6.  Treatment response in Paget's disease.

Authors:  S Patel
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

Review 7.  Paget's disease of bone: diagnosis and management.

Authors:  D Hosking; P J Meunier; J D Ringe; J Y Reginster; C Gennari
Journal:  BMJ       Date:  1996-02-24

Review 8.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 9.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 10.  Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  C J Dunn; A Fitton; E M Sorkin
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.